OBJECTIVE: To investigate the clinical efficacy, safety, tolerability, and toxicity profile of a metabolically stable antifolate, CH-1504, compared to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA). METHODS: A 24-week open-label trial of MTX and CH-1504 was performed in 20 patients with RA. RESULTS: Improvements in clinical and laboratory indicators were observed in both study groups. Improvement in the CH-1504 group was greater than in the MTX group. Both treatments were generally well tolerated; however, the liver function test abnormalities and gastrointestinal related adverse events expected with this class of medication were not seen with CH-1504. CONCLUSION:CH-1504 appears to be clinically efficacious and may possess a superior safety and tolerance profile compared to MTX.
RCT Entities:
OBJECTIVE: To investigate the clinical efficacy, safety, tolerability, and toxicity profile of a metabolically stable antifolate, CH-1504, compared to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA). METHODS: A 24-week open-label trial of MTX and CH-1504 was performed in 20 patients with RA. RESULTS: Improvements in clinical and laboratory indicators were observed in both study groups. Improvement in the CH-1504 group was greater than in the MTX group. Both treatments were generally well tolerated; however, the liver function test abnormalities and gastrointestinal related adverse events expected with this class of medication were not seen with CH-1504. CONCLUSION:CH-1504 appears to be clinically efficacious and may possess a superior safety and tolerance profile compared to MTX.
Authors: Durga M S H Chandrupatla; Gerrit Jansen; Ricardo Vos; Mariska Verlaan; Qingshou Chen; Philip S Low; Albert D Windhorst; Adriaan A Lammertsma; Conny J van der Laken; Carla F M Molthoff Journal: Arthritis Res Ther Date: 2017-05-31 Impact factor: 5.156
Authors: Durga M S H Chandrupatla; Carla F M Molthoff; Adriaan A Lammertsma; Conny J van der Laken; Gerrit Jansen Journal: Drug Deliv Transl Res Date: 2019-02 Impact factor: 4.617